Verastem to present VS-7375 TARGET-D data on Oct 14
Verastem says it will unveil initial efficacy and updated safety data for oral KRAS G12D inhibitor VS-7375 from the TARGET-D trial across pancreatic, lung and colorectal cancers on Oct 14, 2026; BTIG reiterates a $18.00 price target.